sorafenib has been researched along with gw-5074 in 4 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gw-5074) | Trials (gw-5074) | Recent Studies (post-2010) (gw-5074) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 83 | 0 | 51 |
Protein | Taxonomy | sorafenib (IC50) | gw-5074 (IC50) |
---|---|---|---|
Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | 0.23 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.0078 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.23 | |
Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.0146 | |
Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0102 | |
Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | 4.6 | |
Casein kinase II subunit alpha | Homo sapiens (human) | 0.279 | |
Dual specificity tyrosine-phosphorylation-regulated kinase 4 | Homo sapiens (human) | 4.38 | |
Kinesin-like protein KIF15 | Homo sapiens (human) | 2.5 | |
Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 1.89 | |
Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | 5.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aman, W; Hah, JM; Jung, K; Kim, H; Kim, M; Lee, J; Ryu, JS | 1 |
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR | 1 |
Caldwell, GA; Caldwell, KA; Dawson, TM; Dawson, VL; Hamamichi, S; Lee, BD; Liu, Z; Ray, A; Smith, WW; Yang, D | 1 |
Cha, TL; Chang, SY; Chen, MR; Chen, YC; Chuang, MJ; Ho, JY; Hsiao, PW; Huang, SM; Lee, HJ; Lin, CC; Lin, HK; Lin, VC; Sun, GH; Tang, SH; Tsai, YT; Wu, ST; Yu, CP; Yu, DS | 1 |
4 other study(ies) available for sorafenib and gw-5074
Article | Year |
---|---|
Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Structure-Activity Relationship; U937 Cells | 2014 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult | 2009 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Enzyme Activation; Humans; Indoles; Motor Activity; Mutation; Niacinamide; Oxidopamine; Parkinson Disease; Phenols; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Sorafenib; Synucleins | 2011 |
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Topics: Aged; Animals; Apoptosis; Cell Line, Tumor; Death-Associated Protein Kinases; Disease-Free Survival; Drug Synergism; Female; Gene Knockout Techniques; Humans; Indoles; Kidney Neoplasms; Male; Mice; Middle Aged; Mitochondria; Niacinamide; Phenols; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Reactive Oxygen Species; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2015 |